As of 2025-10-29, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -24.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 14,046.45 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-10-28 | -24.42 |
| 2025-10-27 | -24.72 |
| 2025-10-24 | -24.49 |
| 2025-10-23 | -23.80 |
| 2025-10-22 | -24.33 |
| 2025-10-21 | -23.79 |
| 2025-10-20 | -25.46 |
| 2025-10-17 | -26.70 |
| 2025-10-16 | -27.96 |
| 2025-10-15 | -28.83 |
| 2025-10-14 | -27.68 |
| 2025-10-13 | -29.20 |
| 2025-10-10 | -27.16 |
| 2025-10-09 | -28.84 |
| 2025-10-08 | -29.73 |
| 2025-10-07 | -28.38 |
| 2025-10-06 | -28.20 |
| 2025-10-03 | -27.27 |
| 2025-10-02 | -26.54 |
| 2025-10-01 | -26.05 |
| 2025-09-30 | -26.27 |
| 2025-09-29 | -26.92 |
| 2025-09-26 | -26.65 |
| 2025-09-25 | -25.75 |
| 2025-09-24 | -26.06 |
| 2025-09-23 | -24.32 |
| 2025-09-22 | -24.26 |
| 2025-09-19 | -23.98 |
| 2025-09-18 | -24.42 |
| 2025-09-17 | -22.95 |
| 2025-09-16 | -22.99 |
| 2025-09-15 | -24.05 |
| 2025-09-12 | -24.05 |
| 2025-09-11 | -23.61 |
| 2025-09-10 | -22.32 |
| 2025-09-09 | -23.90 |
| 2025-09-08 | -24.70 |
| 2025-09-05 | -33.14 |
| 2025-09-04 | -30.33 |
| 2025-09-03 | -29.96 |
| 2025-09-02 | -30.38 |
| 2025-08-29 | -30.20 |
| 2025-08-28 | -31.13 |
| 2025-08-27 | -31.62 |
| 2025-08-26 | -34.43 |
| 2025-08-25 | -33.52 |
| 2025-08-22 | -33.43 |
| 2025-08-21 | -33.18 |
| 2025-08-20 | -33.00 |
| 2025-08-19 | -32.33 |